Published Data in Hepatocellular Carcinoma
Over 140 peer reviewed publications have assessed the use of SIR-Spheres® Y-90 resin microspheres for HCC.
In addition to the RCTs outlined on previous pages, other studies have demonstrated efficacy and safety of SIR-Spheres Y-90 resin microspheres for patients with HCC. One of these studies showed a significantly increased mOS, in the first-line setting, of 8 months compared with matched controls receiving active treatment or supportive care in patients with unresectable advanced HCC.1
A large retrospective multicentre analysis of SIR-Spheres Y-90 resin microspheres in HCC included first-line and second-line treatment in 325 patients with advanced HCC (ENRY trial).2 All patients received SIR-Spheres Y-90 resin microspheres, and the authors noted the following:
- Survival outcomes compared favourably with transarterial chemoembolisation (TACE)/transarterial embolisation (TAE) for unresectable patients in Barcelona Clinic Liver Cancer (BCLC) stages A and B.
- Benefits of SIR-Spheres Y-90 resin microspheres treatment were particularly favourable for patients with intermediate, BCLC stage B disease who were poor candidates for TACE or had failed TACE/TAE.
- SIR-Spheres Y-90 resin microspheres also showed positive results in patients with advanced stage (BCLC stage C) disease, particularly those with portal vein thrombosis (PVT).
Importantly, OS benefits are suggested with first-line or second-line use of SIR-Spheres Y-90 resin microspheres, irrespective of patient age, presence or absence of PVT, and whether or not the patient has had a previous procedure.2-5
An additional benefit of SIR-Spheres Y-90 resin microspheres is down-staging HCC to potentially curative resection and bridging some patients to transplant.3,4,6,7 These effects can reduce the burden of the disease on the patient, and with down-staging to allow for subsequent curative treatment, the burden on the healthcare systems can be reduced in the longer term.
1 D'Avola D et al. Hepatogastroenterology 2009; 56: 1683-8.
2 Sangro B et al. Hepatology 2011; 54: 868-78.
3 Inarrairaegui M et al. Int J Radiat Oncol Biol Phys 2010; 77: 1441-8.
4 Lau WY et al. Int J Radiat Oncol Biol Phys 1998; 40: 583-92.
5 Golfieri R et al. J Hepatol 2013; 59: 753-61.
6 Gramenzi A et al. Liver Int 2015; 35: 1036-47.
7 Ettorre GM et al. World J Surg 2017; 41: 241-9.